| 1 Gold P,Freedman SO.Demonstration of tumor specific antigen in human colonic carcinoma by immunologic tolerance and absorption techniques[J].J Exp Med, 1965,127:439-462.
2 Chantapet P,Riantawan P,Lebnak P,et aL Utility of serum cytokeralin 19 fragment (CYFRA21-1) and carcinoembryonic antigen(CEA) as tumor marker for nonsmall cell lung cancer[J],J Med Assoc Thai,2000,83(4):383-391.
3王敬慧,张树才,刘志东,等.肺癌患者外周血癌胚抗原、细胞角蛋白19 mRNA表达水平与肿瘤分期、近期疗效及预后的关系[J].中华结核和呼吸杂志,2005,28(11):773-776.
4 Sawabata N,Ohta M,Takeda S,et al.Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer[J].Ann Thorac Surg,2002,74(l):174.
5 Ardizzoni A,Cafferata MA,Tiseo M,et al.Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer[J].Cancer,2006 Dec 15,107(12):2842-49.
6 Jaume T,Joaquim PO,Josep B,et al.Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer[J].Clinical Chemistry,2005,51:219-222.
7 Kulpa J,Wojcik E,Reinfuss M,et al.Carcinoembryonic antigen,squamous cell carcinoma antigen,CYFRA 21 21,and neuron specific enolase in squamous cell lung cancer patients[J].Clin Chem,2002,48(11):1931.
8 Jaume T,Joaquim PO,Josep B,et al.Biological variation of tumor markers and its application in the detection of disease progression in patients with non-small cell lung cancer[J].Clinical Chemistry,2005,51:219-222.
9 Ebert W,Leichtweia B,Schapohler B,et al.The new tumour marker CYFRA21 -1 is superior to SCC antigen and CEA in the primary diagnosis of lung cancer[J]. Tumour Diagn Ther,2003,14(3):91.
10 Schneider J,velcoaky HG,Katz N,et al.Comparison of the tumor marker M2- PK,CEA,CYFRA21-1,NSE and SCC in the diagnosis of lung cancer[J] .Anticancer Res,2000,20(6D):5053-58.
11 Chantapet P,Riantawan P.Lebnak P,et al.Utility of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen(CEA) as tumor marker for non-small cell lung cancer[J].J Med Assoc Thai,2000,83(4):383-391.
12 Fujita J.Dohmoto K,Hojo S,et al.The point mutation in the promoter region and the single nucleotide polymorphism in exon 1 of the cytokeratin 19 gene in human lung cancer cell lines[J].Lung Cancer,2001,34(3):387.
13 Ueda Y,Fujita J,Bandoh S,et al.Expression of cytokeratin 19 mRNA in human lung cancer cell lines[J].Int J Cancer,1999,81(6):939.
14 Tolson J,Bogumil R,Brunst E,et al.Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients [J],Lab Invest,2004,84(7):845-856.
15 Cromer CJ,Campa M,Patz EF.Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of 16 nonsmall cell lung carcinoma[J].Cancer,2004,101(2):379-384.
16戴嵩玮,王小敏,刘丽云,等.一个在肺癌血清中高表达的标志分子SAA的发现及鉴定[J].中国科学C辑:生命科学,2007,37(2):129-134.
17陈永硕.肿瘤标志物的临床应用价值[J].中华检验医学杂志,2002,23 (1):52.
18 Poola I,Graziano SL.Expression of neuron-specific enolase,chromogranin A,synaptophysin and Leu -7 in lung cancer cell lines[J].J Exp Clin Cancer Res, 1998,17(2):165.
19 Satoh H,Ishikawa H,Kurishima K,et al.Cut-off levels of NSE to differentiate SCLC from.NSCLC[J].Oncol Rep,2002,9(3):581.
20 Bonner JA,Sloan JA,Rowland KM,et al.Significance of neuronspecific enolase levels before and during therapy for small cell lung cancer[J],Clin Cancer Res, 2000,6(2):597.
21 Manabu S,Young LC,Munehiro E,et al.Identification of the transforming EML4- ALK fusion gene in non -small -cell lung cancer[J].Nature,2007 August,448: (2):561-566.
22 Hideaki T,Mitsuharu N.Masamichi G,et al.A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma,and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. Modem Pathology,2007,20:638-647.
23 Janina K,Maria K,Beata K,et al.Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer,and correlations with clinicopathological features and prognosis.Oncology,2006,70:115-25.
24 Lin EY,Nguyen AV,Russell RG,et al.Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.(?) Med,2001,193:727-739.
25 Nowicki A,Szenajch J,Ostrowska G,et al.(?)ired tumor growth in colony-stimulating factor 1(CSF-1) -deficient,macrophagedeficient op/op mouse:evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma.Int J Cancer,1996,65:112-119.
26 Bouchnn,Dietrich J.Colonna M.Cutting edge;inflammatory responses can be triggered by TREM-1,a novel receptor expressedcon neutrophils and monocytes[J]. J Immunol,2000,164(10):4991-95.
27 Bouchon A,Facchetti F,Weigand MA,et al.TREM-1 amplifies inflammation and is a crucialmediatorofseptic shock[J].Nature,2001,410(6832):1103-07.
28 Chao-CH,Wei YL,Cheng YW,et al TREM-1 Expression in Tumor-associated Macrophages and Clinical Outcome in Lung Cancer[J].Am J Respir Crit Care Med,2008,1(177):763-770.
29 Lazzaro D,Price M,De Felice M,et al.The transciription factor-1 TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of fetal brain[J].Development,1991,113(4):1093-1104.
30 Srodon M,Westra WH.Immunohistochemical staining for thyroid transcription factor -1:a helpful aid in discerning primary site of tumor origin in patients with brain metastases[J].Hum Pathol,2002,33(6):642-645.
31 Garber ME,Troyanskaya OG,Schluens K.Diversity of gene expression in adenocarcinoma of the lung[J].Proc Natl Acad Sci USA,2001,1998(24):13784-89.
32 Bhattacharjee A,Richards WG,Staunton J,et al.Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses [J].Proc Nad Acad Sci USA,2001,98(24):13790-95.
33 Seog YP.Baek HK,Jung HK.et al.Panels of Immunohistochemical Markers Help Determine Primary Sites of Metastatic Adenocarcinoma[J].Arch Pathol Lab Med,2007,131:1561-67.
34高云朝,王美琴,陆云,等.血清肿瘤标志物检测对肺癌患者的检测价值.中华结核和呼吸杂志,2005,28(4):268-269. |
